Company Legal Name
Latest Valuation
Founded Year
Headquarter
ViCentra develops insulin patch pump technology specifically designed for type 1 diabetics, featuring hybrid closed loop integration capabilities. Based in Utrecht, Netherlands, the company addresses the growing demand for discreet, user-friendly diabetes management solutions that combine continuous glucose monitoring with automated insulin delivery. Their patch pump system offers patients greater mobility and convenience compared to traditional tubed insulin pumps while maintaining the precision required for effective glycemic control. ViCentra operates through its hellokaleido.com platform and focuses on advancing integrated diabetes care technology to improve patient outcomes and quality of life in the expanding digital health market.
Revenue & Revenue Growth Share
Revenue
Revenue Growth
Available in most regions; subject to local regulations.
Open to non-accredited investors with KYC/AML compliance. U.S. investors must meet SEC requirements.
$10 per token, enabling fractionalized access to Pre-IPO shares.
Mandatory identity (KYC) and proof of funds checks.
Variable, applied to investment amounts.
Charged on realized profits.
Tokens may be locked for 6–12 months; resale depends on secondary market liquidity.
Prices reflect past funding rounds, not guaranteed future value.
Biotech depends on regulatory approvals; fintech faces evolving digital asset rules.
Blockchain or custodian issues could delay transfers or verification.
Changing laws may affect tradability or taxation.





